Illumina, Inc. (NASDAQ:ILMN) Position Reduced by Boston Family Office LLC

Boston Family Office LLC reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 59.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 2,773 shares of the life sciences company’s stock after selling 4,060 shares during the quarter. Boston Family Office LLC’s holdings in Illumina were worth $371,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Bank of Stockton grew its stake in shares of Illumina by 3.8% in the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock worth $289,000 after purchasing an additional 80 shares during the last quarter. Stephens Inc. AR boosted its holdings in Illumina by 1.4% during the fourth quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock worth $885,000 after buying an additional 90 shares in the last quarter. Spire Wealth Management grew its position in Illumina by 26.0% in the fourth quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock worth $63,000 after buying an additional 97 shares during the last quarter. IFP Advisors Inc increased its holdings in shares of Illumina by 19.1% in the fourth quarter. IFP Advisors Inc now owns 617 shares of the life sciences company’s stock valued at $82,000 after buying an additional 99 shares in the last quarter. Finally, Brooklyn Investment Group lifted its position in shares of Illumina by 20.5% during the 4th quarter. Brooklyn Investment Group now owns 611 shares of the life sciences company’s stock valued at $82,000 after acquiring an additional 104 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

ILMN stock opened at $78.39 on Wednesday. The firm has a 50 day moving average of $100.39 and a two-hundred day moving average of $126.13. Illumina, Inc. has a 12 month low of $77.54 and a 12 month high of $156.66. The company has a market capitalization of $12.42 billion, a price-to-earnings ratio of -10.21, a P/E/G ratio of 1.60 and a beta of 1.17. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ILMN shares. Hsbc Global Res cut Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. Morgan Stanley dropped their price target on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Royal Bank of Canada cut their price objective on Illumina from $247.00 to $128.00 and set an “outperform” rating on the stock in a report on Wednesday, March 12th. Piper Sandler raised their target price on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Finally, Guggenheim cut their price target on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $140.90.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.